Developmental Research Program
**2010-2011 CALL FOR RESEARCH PROPOSALS**The Uterine SPORE is currently soliciting proposals for 2010-2011 Developmental Research (Pilot Project) funding. Please download and review the Pilot Project RFA (pdf) for specific details. |
Directors
Thomas W. Burke, M.D. and Peter J. Davies, M.D., Ph.D.
The overall goal of the University of Texas M. D. Anderson Cancer Center Gynecologic SPORE for Uterine Cancers Developmental Research Program is to provide initial funding to support innovative translational studies and exploratory research in the area of gynecologic oncology and uterine cancer research. The support of translational research projects that can generate clinically testable hypotheses aimed at reducing the incidence and mortality of uterine cancers or leading to improved therapeutic outcomes or quality of life for uterine cancer patients will be emphasized.
Each year, pre-proposals in the form of project abstracts (1/2 -1 page) are solicited by the program, and applicants of responsive abstracts are invited to submit full pilot project proposals to the program. Proposals follow an abbreviated R01 research grant format and are up to 5 pages in length. The Developmental Research Program Directors, in conjunction with the SPORE Executive Committee, help investigators submitting proposals in formulating relevant translational research aims and plans, as many investigators may not have previous expertise in this area. This process is therefore a major educational activity with a goal to further stimulate translational research in gynecologic oncology and encourage the participation of both basic researchers and clinicians in translational research. With input from the Internal and External Advisory Committees, the SPORE Executive Committee makes the final selection of Pilot Projects for funding. Projects are funded for 1 year with the possibility of competitive renewal for an additional year. The program strives to fund at least 2 pilot projects each year. All projects are reviewed at the end of their first year with written progress reports and oral presentations at one of the SPORE meetings or retreats. Projects receiving an additional year of support will submit a final progress report at the end of their second year.
Funding Information
- Solicitations for proposals come out late spring/early summer each year.
- Funding is for $50,000 total costs.
- Funding is for 1 year beginning September 1 and ending August 31 each year.
- A progress report will be due at the end of the funding period.
- Competitive renewal for 1 additional year is allowed.
Please call or email Jennifer Stanley (713-792-8451, jlstanle@mdanderson.org) for further information or to get on the email list for solicitations. Also, you may check the SPORE website for updates on solicitations.
Developmental Research Awards
2003-2004
- Jennifer K. Richer, Ph.D., and Meenakshi Singh, M.D.
University of Colorado Health Sciences Center
Alterations in co-activator levels in endometrial cancer - Richard R. Behringer, Ph.D.
UT MD Anderson Cancer Center
Transgenic mice for endometrium-specific modifications
2004-2005
- Mark T. Bedford, Ph.D.
UT MD Anderson Cancer Center
Arginine methyltransferases as novel therapeutic targets for endometrial carcinoma - Diego H. Castrillon, M.D., Ph.D.
UT Southwestern
Genetic mechanisms of endometrial carcinogenesis - Shi-Wen Jiang, M.D. and Sean Dowdy, M.D.
Mayo Clinic
Preclinical studies on epigenetic modification reagents for endometrial cancer treatment
2005-2006
- Donghai Dai, M.D., Ph.D.
University of New Mexico Health Science Center
Synergistic anti-cancer effect of paclitaxel and amifostine in poor outcome endometrial cancer
2006-2007
- Constance T. Albarracin, M.D., Ph.D.
UT MD Anderson Cancer Center
MicroRNA profiling to identify functional gene targets in endometrial carcinoma
2007-2008
- Bo Rueda, Ph.D.
Harvard Medical School
Delineating the unique gene expression features of the endometrial tumor initiating cell fraction - Jae-Wook Jeong, Ph.D.
Baylor College of Medicine
The role of Mig-6 in the tumorigenesis of endometrial cancer - Anil K. Sood, M.D. and Robert Coleman, M.D.
UT MD Anderson Cancer Center
EphA2 targeting for anti-vascular therapy of endometrial carcinoma
2008-2009
- Anil K. Sood, M.D. and Robert Coleman, M.D. (Renewal)
UT MD Anderson Cancer Center
EphA2 targeting for anti-vascular therapy of endometrial carcinoma